Overview of seizure-inducing potential of doripenem

Drug Safety

Volumn 32, Issue 9, 2009, Pages 709-716

  Zhanel, George G ^a,c   Ketter, Nzeera ^b   Rubinstein, Ethan ^a   Friedland, Ian ^b   Redman, Rebecca ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CILASTATIN PLUS IMIPENEM; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PANIPENEM; PANIPENEM PLUS BETAMIPRON; PENTETRAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VALPROIC ACID;

ABDOMINAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOTE; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SUBARACHNOID HEMORRHAGE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CARBAPENEMS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES; YOUNG ADULT;

EID: 68849086083     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932090-00001     Document Type: Note

References (32)

1. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of betalactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 1991 Apr; 27 (4): 405-25
2. Wallace KL. Antibiotic-induced convulsions. Crit Care Clin 1997 Oct; 13 (4): 741-62
3. Primaxin IV (imipenem and cilastin for injection) [package insert]. Whitehouse Station (NJ): Merck & Co. Inc., 2005
4. Alvan G, Nord CE. Adverse effects of monobactams and carbapenems. Drug Saf 1995 May; 12 (5): 305-13
5. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006 Nov; 58 (5): 916-29
6. Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother 2000 Jan; 45 (1): 5-7
7. O'Donovan CA, White ML, Cheung A, et al. Seizure incidence with imipenem use at a VA hospital. Hosp Formul 1995 Mar; 30: 172-5
8. Townsend KA, Alaniz C, Stumpf JL, et al. Imipenem-cilastatin use: evaluation of dosing and survey of adverse effects. Hosp Pharm 1992;27: 298, 303-5, 8-10
9. Wong VK, Wright Jr HT, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991 Feb; 10 (2): 122-5
10. Pestotnik SL, Classen DC, Evans RS, et al. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmac-other 1993 Apr; 27 (4): 497-501
11. Hoffman J, Trimble J, Brophy GM. Safety of imipenem/cilastatin in neurocritical care patients. Neurocrit Care 2009;103: 403-7
12. Merrem IV (meropenem for injection) [package insert]. Wilmington (DE): AstraZeneca Pharmaceuticals, 2005
13. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999;31(1): 3-10
14. Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007;30(8): 657-68
15. Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf 2000 Mar; 22 (3): 191-4
16. Invanz (ertapenem for injection) [package insert]. White-house Station (NJ): Merck & Co. Inc., 2006
17. Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004 Jun; 53 Suppl. 2: ii75-81
18. Shah PM, Isaacs RD. Ertapenem: the first of a new group of carbapenems. J Antimicrob Chemother 2003 Oct; 52 (4): 538-42
19. Doribax (doripenem for injection) [package insert]. Raritan (NJ): Ortho-McNeil Pharmaceutical Inc., 2008
20. Ge Y, Wikler MA, Sahm DF, et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1384-96
21. Jones RN, Stilwell MG, Sader HS, et al. Uniformly enhance activity of doripenem compared to other carbapenems (imipenem, meropenem) when testing P. aeruginosa isolates: results from three continents. Int J Infect Dis 2006;10 Suppl. 1: S127-8
22. Horiuchi M, Kimura M, Tokumura M, et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006 May 1;222(1-2): 114-24
23. Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004 Dec; 32 (12): 1383-91
24. Doribax [package insert]. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals Inc., 2007
25. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and toler-ability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, non-inferiority study. Clin Ther 2008 May; 30 (5): 868-83
26. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multi-center study. Curr Med Res Opin 2008 Jul; 24 (7): 2113-26
27. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008 Apr; 36 (4): 1089-96
28. Johnson & Johnson Pharmaceutical Research & Development LLC. Cumulative post-marketing review of seizures associated with the use of DORIBAX/FINNIBAX. (doripenem) 27 June 2008; EDMS PSDB-8580935. Raritan (NJ); Johnson & Johnson Pharmaceutical Research & Development LLC., 2008
29. Keam SJ. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 2008;68(14): 2021-57
30. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988 May; 84 (5): 911-8
31. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67(7): 1027-52
32. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008 Jan; 9 (1): 23-37